Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Adaxion Therapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action involves 1 distinct examiner and 1 distinct art unit. The singular nature of this activity suggests a very specific focus for the company's current patent efforts. Managing only 1 pending office action allows the applicant to provide a comprehensive and targeted response to the technical issues identified by the patent office.
ALDARONDO, DASIA ALI is the busiest examiner, holding 1 busiest examiner pending action. This represents the total pending workload for the company's portfolio. Effective prosecution will require a targeted response to the specific issues identified by this examiner within the 1 distinct art unit. Practitioners should prioritize understanding the examiner's perspective, as the resolution of this 1 pending office action is the primary goal for the company's current intellectual property strategy in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18351367 | Autoantigens Engineered to Suppress Autoimmune Response | ALDARONDO, DASIA ALI | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18351367 | Autoantigens Engineered to Suppress Autoimmune Response | ALDARONDO, DASIA ALI | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdaxion Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dasia Ali Aldarondo has the most, with 1 of Adaxion Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
